Literature DB >> 25048573

Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases.

Pavla Veselá1, Zbyněk Tonar, David Sálek, Samuel Vokurka, Marek Trněný, Roman Kodet, Mojmír Moulis, Petra Kašparová, Zdeňka Vernerová, Zuzana Velenská, Jan Stříteský, Michal Michal, Ludmila Boudová.   

Abstract

The clinical course and therapy of mantle cell lymphoma (MCL) are heterogeneous and often unsatisfactory. Prognostic factors are needed to stratify the patients. Microvessel density (MVD) has prognostic significance in some malignancies. There is little information about the vasculature of MCL, although some antiangiogenic drugs are in use. We studied MVD using systematic uniform random sampling and unbiased counting frames in immunohistochemical reactions with anti-CD34 antibody in pre-therapeutic extramedullary MCL samples of 177 patients. We analyzed the relationship of MVD to overall survival (OS) and progression-free survival (PFS), as well as to proliferative activity (Ki-67), mantle cell lymphoma prognostic index (MIPI), morphological variant, pattern of growth, and localization. MVD varied widely: range 54.6-503.6 vessels/mm(2), median 158.2 vessels/mm(2). Higher MVD was associated with bone marrow infiltration at the time of diagnosis (P = 0.001). High MVD was associated with significantly worse OS (P = 0.04) only in patients treated with non-intensive (conventional) therapy. MVD correlated positively with MIPI scores but not with the proliferation, morphological variant, growth pattern, or localization. Univariate analysis identified a prognostic influence of morphological variant, MIPI, and proliferative activity on OS and PFS and a prognostic influence of bone marrow infiltration at the time of diagnosis on PFS. Multivariate analysis showed prognostic influence of MIPI and proliferative activity on OS and PFS only. In conclusion, this is the first clinicopathological study of MVD of MCL with long-term follow-up showing negative prognostic trends of high MVD in MCL and positive correlation of MVD and MIPI.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25048573     DOI: 10.1007/s00428-014-1632-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  39 in total

1.  Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.

Authors:  Eva Hoster; Wolfram Klapper; Olivier Hermine; Hanneke C Kluin-Nelemans; Jan Walewski; Achiel van Hoof; Marek Trneny; Christian H Geisler; Francesco Di Raimondo; Michal Szymczyk; Stephan Stilgenbauer; Catherine Thieblemont; Michael Hallek; Roswitha Forstpointner; Christiane Pott; Vincent Ribrag; Jeanette Doorduijn; Wolfgang Hiddemann; Martin H Dreyling; Michael Unterhalt
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

2.  Treatment of older patients with mantle-cell lymphoma.

Authors:  H C Kluin-Nelemans; E Hoster; O Hermine; J Walewski; M Trneny; C H Geisler; S Stilgenbauer; C Thieblemont; U Vehling-Kaiser; J K Doorduijn; B Coiffier; R Forstpointner; H Tilly; L Kanz; P Feugier; M Szymczyk; M Hallek; S Kremers; G Lepeu; L Sanhes; J M Zijlstra; R Bouabdallah; P J Lugtenburg; M Macro; M Pfreundschuh; V Procházka; F Di Raimondo; V Ribrag; M Uppenkamp; M André; W Klapper; W Hiddemann; M Unterhalt; M H Dreyling
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

3.  High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.

Authors:  Teresa M Cardesa-Salzmann; Luis Colomo; Gonzalo Gutierrez; Wing C Chan; Dennis Weisenburger; Fina Climent; Eva González-Barca; Santiago Mercadal; Leonor Arenillas; Sergio Serrano; Ray Tubbs; Jan Delabie; Randy D Gascoyne; Joseph M Connors; Jose L Mate; Lisa Rimsza; Rita Braziel; Andreas Rosenwald; Georg Lenz; George Wright; Elaine S Jaffe; Louis Staudt; Pedro Jares; Armando López-Guillermo; Elias Campo
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

4.  Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting.

Authors:  Saskia A M van de Schans; Maryska L G Janssen-Heijnen; Marten R Nijziel; Ewout W Steyerberg; Dick Johan van Spronsen
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

5.  Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy.

Authors:  Minna Taskinen; Esa Jantunen; Veli-Matti Kosma; Petri Bono; Marja-Liisa Karjalainen-Lindsberg; Sirpa Leppä
Journal:  Eur J Cancer       Date:  2010-07-12       Impact factor: 9.162

6.  Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy.

Authors:  Dita Gratzinger; Shuchun Zhao; Robert J Tibshirani; Eric D Hsi; Christine P Hans; Brad Pohlman; Martin Bast; Abraham Avigdor; Ginette Schiby; Arnon Nagler; Gerald E Byrne; Izidore S Lossos; Yasodha Natkunam
Journal:  Lab Invest       Date:  2007-11-12       Impact factor: 5.662

7.  Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki-67.

Authors:  Yoshizo Kimura; Kensaku Sato; Fumiko Arakawa; Kennosuke Karube; Yuko Nomura; Kei Shimizu; Ryosuke Aoki; Keiko Hashikawa; Shiro Yoshida; Junichi Kiyasu; Masanori Takeuchi; Daisuke Nino; Yasuo Sugita; Toshiaki Morito; Tadashi Yoshino; Shigeo Nakamura; Masahiro Kikuchi; Koichi Ohshima
Journal:  Cancer Sci       Date:  2009-11-13       Impact factor: 6.716

8.  Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.

Authors:  C Schrader; P Meusers; G Brittinger; A Teymoortash; J-U Siebmann; D Janssen; R Parwaresch; M Tiemann
Journal:  Leukemia       Date:  2004-07       Impact factor: 11.528

9.  Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

Authors:  Olaf Determann; Eva Hoster; German Ott; Heinz Wolfram Bernd; Christoph Loddenkemper; Martin Leo Hansmann; Thomas E F Barth; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling; Wolfram Klapper
Journal:  Blood       Date:  2007-12-12       Impact factor: 22.113

10.  Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.

Authors:  R Schaffel; C V Hedvat; J Teruya-Feldstein; D Persky; J Maragulia; D Lin; C S Portlock; C H Moskowitz; A D Zelenetz
Journal:  Ann Oncol       Date:  2010-01       Impact factor: 32.976

View more
  3 in total

1.  IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme.

Authors:  Jiří Polívka; Martin Pešta; Pavel Pitule; Ondřej Hes; Luboš Holubec; Jiří Polívka; Tereza Kubíková; Zbyněk Tonar
Journal:  Oncotarget       Date:  2018-02-20

2.  A long-term retrospective study on sporadic Burkitt lymphoma in chinese population.

Authors:  Xiaoyun Yang; Qianru Huang; An Li; Yuan Chen; Wei Xu; Jianyong Li; Yaping Wang; Yongjun Fang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

3.  Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas.

Authors:  Radek Jakša; Jana Karolová; Michael Svatoň; Dmitry Kazantsev; Martina Grajciarová; Eva Pokorná; Zbyněk Tonar; Magdalena Klánová; Lucie Winkowska; Diana Maláriková; Petra Vočková; Kristina Forsterová; Nicol Renešová; Alexandra Dolníková; Kristýna Nožičková; Pavel Dundr; Eva Froňková; Marek Trněný; Pavel Klener
Journal:  Lab Invest       Date:  2022-04-29       Impact factor: 5.502

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.